Guggenheim Analyst Reiterates Buy Rating on Prime Medicine with Revised Price Target
Guggenheim analyst Debjit Chattopadhyay has reiterated his Buy rating on Prime Medicine (NASDAQ: PRME) on March 5, 2024, while adjusting ...
Guggenheim analyst Debjit Chattopadhyay has reiterated his Buy rating on Prime Medicine (NASDAQ: PRME) on March 5, 2024, while adjusting ...
StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.